Cure Today

MDS Treatment Advances: Targeted Therapies and Anemia Management

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
The American Journal of Managed Care

ESA Treatment Improves OS in Lower-Risk MDS

ESA treatment in lower-risk MDS patients is linked to improved overall survival and quality of life. Avoiding red blood cell transfusions is associated with significantly better health-related quality ...
Reader's Digest

Progress in Treatment Options for Anemia Due to MDS

Dr. Shah was compensated by BMS for his participation. Photo Credit: Shutterstock As you age, feeling tired or short of breath may be dismissed as a part of getting older, but it’s important to talk ...
The American Journal of Managed Care

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point. The phase 3 ...
Business Wire

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Cure Today

EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS

Rytelo is approved for low-risk MDS patients with transfusion-dependent anemia, excluding those with isolated deletion 5q. Phase 3 IMerge trial data demonstrated significant reduction in red blood ...
Monthly Prescribing Reference

Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes

Credit: Getty Images. The approval was based on data from the pivotal phase 3 COMMANDS trial that compared luspatercept to epoetin alfa in 356 patients with anemia and lower-risk MDS. The Food and ...
Business Wire

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Seeking Alpha

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted ...
MedPage Today

Telomerase Inhibitor Approved for MDS-Related Anemia

The FDA approved imetelstat (Rytelo) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia who failed or cannot take standard treatment, the ...
Healio

Luspatercept ‘a paradigm shift’ in transfusion-dependent myelodysplastic syndrome

Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...